NEW: “NOVA AI.”, the first agentic agent to match companies to exited founders and capital

Seed to decacorn in under four years.

Company

Colossal Biosciences

Industry

Biotech

Company Size

Series C · $600M+ raised · $10.2B valuation.

The signal

day one, before the first advisor was named or the first dollar raised.

The challenge

a brand-new company with a moonshot mission needed its first advisors and its first round of capital.

The Supernova advantage

exited founders building together from day one, which brought the right advisors and investors to the table faster.

The impact

with Colossal from seed through a $10.2B valuation and $600M+ raised.

Seed to decacorn · Biotech · Founding advisor plus exited-founder placements

Seed to decacorn in under four years.

Ben Lamm had built and exited companies before. He wanted to bring in the world's best to bring his mission to fruition.

Supernova started with Colossal at seed. It was our first portfolio company. Barry Stamos joined as founding advisor, recruited Peter Diamandis to the advisory board, and introduced investors who joined the first round.

Peter has since co-founded NeoGenesis Capital, a $200M venture fund built to back Colossal and the companies that grow out of its platform. That is what can happen when exited founders build together.

"They advise me. I advise others. That's the Supernova effect! When exited founders team up results happen faster."

Ben Lamm

CEO and Co-founder, Colossal Biosciences

With Colossal since seed · Decacorn within four years · Supernova's first portfolio company · Peter Diamandis placed on the advisory board · NeoGenesis Capital launched October 2026 to back the Colossal platform

supernova

Ready to go Supernova?

Book a Call
supernovasupernova